EvoGene™

Humanisation of an antibody can result in a decreased tightness of its attachment to the target and therefore lower potency. This can be restored or greatly improved, by the application of EvoGene™ technology.

The EvoGene™ process involves the production of billions of different, slightly mutated variants of the starting product, testing of these variants for improved binding activity to the target and selection of the best. These two steps are then repeated to select engineered antibodies with the best properties arising from the fewest mutations.

EvoGene™ uses a unique proprietary mutagenesis that enhances the randomness of the mutations created to give a high level of diversity, which is maintained by directly accessing the mutants using a technique referred to as ribosome display. Competitor approaches such as phage display require a transformation step that is associated with a significant loss in diversity.

The process has been validated extensively. It is not specific for antibodies and can be applied to any protein to increase its value as a therapeutic.